Next Article in Journal
Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer
Next Article in Special Issue
The Importance of the PI3K/AKT/MTOR Pathway in the Progression of Ovarian Cancer
Previous Article in Journal
Sphingomyelin in High-Density Lipoproteins: Structural Role and Biological Function
Previous Article in Special Issue
Regulation of Ovarian Cancer Stem Cells or Tumor-Initiating Cells
Article Menu

Export Article

Open AccessReview
Int. J. Mol. Sci. 2013, 14(4), 7742-7756;

Aberrant Lipid Metabolism: An Emerging Diagnostic and Therapeutic Target in Ovarian Cancer

Discipline of Obstetrics and Gynaecology, School of Paediatrics and Reproductive Health, Research Centre for Reproductive Health, Robinson Institute, University of Adelaide, Adelaide 5005, Australia
Genetics and Molecular Pathology, SA Pathology, Women's and Children's Hospital, Adelaide 5006, Australia
Department of Gynaecological Oncology, Royal Adelaide Hospital, Adelaide 5000, Australia
Author to whom correspondence should be addressed.
Received: 1 February 2013 / Revised: 6 March 2013 / Accepted: 7 March 2013 / Published: 10 April 2013
(This article belongs to the Special Issue Genes and Pathways in the Pathogenesis of Ovarian Cancer)
Full-Text   |   PDF [193 KB, uploaded 19 June 2014]


Ovarian cancer remains the most lethal gynaecological cancer. A better understanding of the molecular pathogenesis of ovarian cancer is of critical importance to develop early detection tests and identify new therapeutic targets that would increase survival. Cancer cells depend on de novo lipid synthesis for the generation of fatty acids to meet the energy requirements for increased tumour growth. There is increasing evidence that lipid metabolism is deregulated in cancers, including ovarian cancer. The increased expression and activity of lipogenic enzymes is largely responsible for increased lipid synthesis, which is regulated by metabolic and oncogenic signalling pathways. This article reviews the latest knowledge on lipid metabolism and the alterations in the expression of lipogenic enzymes and downstream signalling pathways in ovarian cancer. Current developments for exploiting lipids as biomarkers for the detection of early stage ovarian cancer and therapeutic targets are discussed. Current research targeting lipogenic enzymes and lipids to increase the cytotoxicity of chemotherapy drugs is also highlighted. View Full-Text
Keywords: ovarian cancer; lipid synthesis; signalling pathways; biomarkers; therapeutic targets ovarian cancer; lipid synthesis; signalling pathways; biomarkers; therapeutic targets
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Pyragius, C.E.; Fuller, M.; Ricciardelli, C.; Oehler, M.K. Aberrant Lipid Metabolism: An Emerging Diagnostic and Therapeutic Target in Ovarian Cancer. Int. J. Mol. Sci. 2013, 14, 7742-7756.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top